[1] 王中和. 口腔颌面-头颈肿瘤放射治疗学[M]. 上海: 上海世界图书出版公司, 2013.
[2] Prasasya RD, Tian D, Kreeger PK. Analysis of cancer signaling networks by systems biology to develop therapies[J]. Semin Cancer Biol, 2011, 21(3):200-206.
[3] Freidlin B, McShane LM, Polley MY, et al. Randomized phase II trial designs with biomarkers[J]. J Clin Oncol, 2012, 30(26): 3304-3309.
[4] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6):567-578.
[5] Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck--An update[J]. Oral Oncol, 2015, 51(7):652-661.
[6] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1):21-28.
[7] Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5):343-349.
[8] Lu T, Zhao C, Chen C, et al. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma(NPC): preliminary report[J]. J Clin Oncol, 2010, 28(15):5577-5577.
[9] Cohen EE, Haraf DJ, Kunnavakkam R, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer[J]. J Clin Oncol, 2010, 28(20):3336-3343.
[10] Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):696-702.
[11] Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors[J]. Cell, 2014, 156(4):744-758.
[12] Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298-307.
[13] Almangush A, Heikkinen I, Makitie AA, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis[J]. Br J Cancer, 2017, 117(6):856-866.
[14] Kuwahara Y, Mori M, Kitahara S, et al. Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors[J]. Cancer Med, 2014, 3(2):310-321.
[15] Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7): 1253-1256.
[16] Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies[J]. Head Neck, 2008, 30(2):262-266.
[17] Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer[J]. J Clin Oncol, 2011, 29(9):1140-1145
[18] Li L, Liu RY, Huang JL, et al. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma[J]. Int J Cancer, 2006, 118(8):2064-2071.
[19] 秦叔逵, 李进. 阿帕提尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9):841-847.
[21] Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study[J]. Oral Oncol, 2003, 39(7):724-727.
[23] Ghosal N, Mais K, Shenjere P, et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma[J]. Br J Oral Maxillofac Surg, 2011, 49(7):510-515.
[24] Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC[J]. Ann Oncol, 2012, 23(6):1562-1570.
[25] Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies[J]. Cancer Biol Ther, 2013, 14(4):304-314.
[26] Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer[J]. Cancer Res, 2013, 73(11):3381-3392.
[27] Calzone L, Kuperstein I, Cohen D, et al. Biological network modelling and precision medicine in oncology[J]. Bull Cancer, 2014, 101(Suppl 1):S18-S21.
[28] Papadatos-Pastos D, De Miguel Luken MJ, Yap TA. Combining targeted therapeutics in the era of precision medicine[J]. Br J Cancer, 2015, 112(1):1-3.
[29] Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies[J]. CA Cancer J Clin, 2013, 63(4):249-279.
[30] Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality[J]. Ann Oncol, 2014, 25(12):2304-2313.
[31] Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations[J]. Semin Oncol, 2015, 42(3):363-377.
[32] Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy[J]. Eur J Immunol, 2015, 45(7):1892-1905. |